Live tape
Top 8, mentions 7d14,342NVDA4,856 mentions▲ +0.04GOOGL2,061 mentions▲ +0.04SPY1,737 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,107 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK861 mentions▲ +0.05

Equity · Healthcare

FDMT

NASDAQ

4D Molecular Therapeutics (FDMT)

10.98 USD −0.18% vs prior close
4D Molecular Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
759.5M USD
Revenue, year to Dec 2025
85.2M USD
EPS, diluted, year to Dec 2025
−2.42 USD
52-week range
4.16 USD – 13.32 USD
Avg volume
193.5K

as of Jul 17, 2026

Have 4D Molecular Therapeutics (FDMT) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, 4D Molecular Therapeutics insiders reported 8 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 9 Oct 2025, show no open-market purchase.

Form 4, 90 days to 10 Nov 2026, newest reported trade 16 Oct 2026

0buys
8sells
$2.74Mnet sold
6other filings
Have 4D Molecular Therapeutics (FDMT) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
16 Oct 2026Bizily ScottChief Legal OfficerSell1,63521K USD
05 Oct 2026Kirn DavidSee RemarksSell58,333754K USD
16 Sep 2026Bizily ScottChief Legal OfficerSell1,63522K USD
14 Sep 2026Kirn DavidSee RemarksSell58,333811K USD
01 Sep 2026Bizily ScottChief Legal OfficerSell5848K USD
19 Aug 2026Kirn DavidSee RemarksSell69,0761.1M USD
17 Aug 2026Bizily ScottChief Legal OfficerSell1,63520K USD
13 Aug 2026Bizily ScottChief Legal OfficerSell1,63520K USD
Sold8 open-market sales192,866$2.74M
6 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have 4D Molecular Therapeutics (FDMT) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
16 Oct 2026Bizily ScottChief Legal OfficerOption exercise1,6357K USD
16 Sep 2026Bizily ScottChief Legal OfficerOption exercise1,6357K USD
01 Sep 2026Bizily ScottChief Legal OfficerOption exercise5844K USD
19 Aug 2026Kirn DavidSee RemarksOption exercise50,000207K USD
17 Aug 2026Bizily ScottChief Legal OfficerOption exercise1,6357K USD
13 Aug 2026Bizily ScottChief Legal OfficerOption exercise1,6357K USD

Which funds hold 4D Molecular Therapeutics (FDMT)?

1 of the 45 institutional funds we track reported a 4D Molecular Therapeutics position for the quarter ended 30 Sep 2026 — a combined 838K USD; the latest of those filings landed 06 Nov 2026.

Form 13F

Which funds hold 4D Molecular Therapeutics (FDMT)?
FundPositionSharesValueShares q/q
Fisher Asset ManagementHeld (±25%)58,546838K USD−11.0%

What has been filed or recorded for 4D Molecular Therapeutics (FDMT)?

The filings we hold for 4D Molecular Therapeutics, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 07 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for 4D Molecular Therapeutics (FDMT)?
And
07 Oct 2026Fails to deliverShares failed to deliver6,973 shares88K USD notional · 0.010% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −1.04 USDRevenue $4M
30 Jun 2026FinancialsTotal assets492.6M USDat period end
30 Jun 2026FinancialsTotal equity407.7M USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −1.01 USDRevenue $3M
31 Dec 2025Annual reportFY 2025 reportedEPS −2.42 USDRevenue $85M
31 Dec 2025FinancialsRevenue85.2M USDfiscal year
31 Dec 2025FinancialsNet income−140.1M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−2.42 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −1.01 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.98 USDRevenue $0M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.86 USDRevenue $0M
31 Dec 2024Annual reportFY 2024 reportedEPS −2.98 USDRevenue $0M
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −0.79 USDRevenue $0M

What do people ask about 4D Molecular Therapeutics (FDMT)?

From live data
What is 4D Molecular Therapeutics’ market cap?759.5M

4D Molecular Therapeutics is worth 759.5M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is 4D Molecular Therapeutics’ revenue?85.2M

4D Molecular Therapeutics reported revenue of 85.2M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have 4D Molecular Therapeutics insiders bought or sold shares recently?8 sales

In the 90 days to 10 Nov 2026, 4D Molecular Therapeutics insiders reported 8 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 9 Oct 2025, show no open-market purchase. A further 6 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own 4D Molecular Therapeutics?1 of 45

1 of the 45 funds we track reported a 4D Molecular Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds

When did 4D Molecular Therapeutics last report earnings?−1.04

4D Molecular Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −1.04 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings